ARCTIC Chill Descends On AstraZeneca's Imfinzi/Treme Combo In NSCLC
Failure of the ARCTIC study was considered likely and will do little to dent Imfinzi's overall sales prospects but cools sentiment on the CTLA4 inhibitor tremelimumab.
You may also be interested in...
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
Against all the odds, AstraZeneca still has hopes for Imfinzi in first-line NSCLC with data from the failed MYSTIC trial suggesting strong survival in patients with a high tumour mutation burden.
The latest failure of the combination of AZ's PD-L1 inhibitor and its CLTA4 inhibitor is in advanced head and neck cancer. It follows recent failures of the MYSTIC and ARCTIC trials in lung cancer.